Company (Symbol) Funding Institution Amount (M) Type Details (Date) Aastrom Biosciences Inc. (ASTM) National Cancer Institute $0.11 Phase I SBIR grant To study the AastromReplicell System in enhancing the immunostimulatory potency of dendritic cell-based cancer vaccines (9/30) Aastrom Biosciences Inc. (ASTM) National Cancer Institute $0.12 Phase I SBIR grant For eight-month study to demonstrate feasibility of using its cell-production technology to develop an immunotherapeutic for

Managing Editor Amid a fast warm-up and high expectations the market is a go The development of the RNAi biotechnology sector has been generally managing according to projection on its fundamental levels since its discovery and as the market segment progresses toward clinical trials that it envisions will eventually deliver therapeutics to market. There have been problems, such as the intellectual property disputes and uncertainty associated with anticipated entry into clinical trials, but

Conducted By Michael J. Harris, Managing Editor Interview with John McKinley, Chairman and CEO, Benitec, Ltd

Conducted By Michael J. Harris, Managing Editor Interview with Steve Kriegsman, President and CEO, CytRx Corporation How did your agreement with University of Massachusetts Medical School contribute to CytRx's start in the field of RNAi

Conducted By Michael J. Harris, Managing Editor Interview with Nassim Usman, Ph.D., COO and Sr

In the laboratory, RNAi has perceptibly become the method of choice for a wide range of biomedical applications and has emerged as the most effective and preferred new functional genomics screening tool for identification and validation of new therapeutic drug targets.

Managing Editor Reagent market helps account for fast start of the general RNAi market The RNAi reagent/research materials industry is an established market, fully capable of supplying the research needs of the relative biotechnology drug development market. Conveyance of drugs to target cellular areas is a fundamental element in the discovery and administration of therapeutics, and RNAi research is effectively using intelligence obtained from the study of the successes and limitations of

Managing Editor The RNAi patent litigation market gets off to a thriving start The fact that there are presently more RNAi litigation cases than there are RNAi products, or even relative clinical trials, puts a perspective on the state of the technology and industry, as well as the impending importance of intellectual property issues on the future of therapeutic development. Litigation in the current patent landscape is the major issue facing RNAi technology, as there is confusion over

If so, RNAi will facilitate its own cogency and may come to be regarded as the zeitgeber that energized and paced the biotechnology industry into the 21st century.

in one, Perlegen is studying drug response in patients with major depression disorder and the other focuses on research in markers associated with metabolic syndromes. (See BioWorld Today, Jan. 12, 2004.) Later last year, Perlegen won a $2.8 million grant from the Michael J. Fox Foundation for Parkinson's Research, in which the company is working with the Mayo Clinic in Rochester, Minn., to determine SNPs related to Parkinson's disease

For our next step, we have initiated discussions with patient advocate organizations, such as the Michael J. Fox Foundation, and other research-funding agencies," Rothschild said, adding that Amgen is working to make GDNF available to preclinical researchers and will publish Phase II and toxicology data

The Michael J. Fox Foundation for Parkinson's Research in New York awarded grants totaling nearly $1 million to four researchers through its Cell Line II program, "Cell Replacement Therapy: Developing Dopaminergic Cell Lines With Long-Lasting Functional Impact in Transplant Models of Parkinson's Disease

The Michael J. Fox Foundation for Parkinson's Research in New York created a drug discovery and development program to address obstacles that impede progress in bringing new Parkinson's therapies to market

Company Name of Executive Age Base Salary ($000) Bonus ($000) Total ($000) Other ($000) Long-Term Compensation ($000) Total Direct Compensation ($000) Base Salary Prior FY ($000) Percent Change Base Salary (%) Potential Realizable Value of Option Grants ($000) FYE Value of Exercisable In-the-Money Options ($000) Percent of Co. Stock Owned By CEO (%) Cum. Total Return on Investment ($) Stock Price 12/31/02 ($) Stock Price 12/31/03 ($) Percent Change Stock Price (%) Shares Out (M

314 150 464 1.86 34.8 64.7 122 Richard Otto (30) Corautus Genetics Inc. (a) 273 188 461 4.5 12.4 55.8 123 Michael J. Gausling Oscient Pharma Corp

Lawrence D. Jones (4) 183 5 188 6 0 194 112 172 Alkermes Inc.* Michael J. Landine (5) 258 28 286 6 0 292 422 68 Alteon Inc...Michael J. Howerton (21) 266 125 391 2 0 393 873 135 Imcor Pharmaceutical Co

Michael J. Howerton (20) 266 125 391 7 Neurocrine Biosciences Inc...Robert Weisskoff 212 76 288 23 Alkermes Inc.* Michael J. Landine (5) 258 28 286 24 Dyax Corp

Michael J. Howerton (39) 266 125 391 2 0 393 873 135 Imcor Pharmaceutical Co

284 53 337 47 Michael J. Jeffries Osteotech Inc...143 0 143 162 Richard W. Reichow (7) Aeolus Pharmaceuticals Inc. *** 141 0 141 163 Joseph A. Markey (81) Valentis Inc.** 138 0 138 164 Michael J. Draper (77) Transgenomic Inc